Plusultra pharma Information

Plusultra pharma is dedicated to bringing treatments for rare diseases to the European Market. Our goals are to improve patient’s quality of life where possible and use our expertise to ensure high quality products are available . Plusultra pharma GmbH was founded in 2020 as a subsidiary company of the Japanese Company Nobelpharma Co. Ltd. Our European Headquarters are based in Düsseldorf, Germany. In the same year, Plusultra Pharma UK Ltd. was founded in the United Kingdom. We have been working together closely ever since to reach our common goal of providing much needed drugs for rare diseases (Orphan Drugs) and Medical Devices to patients in the EU and UK. Following approval by the EMA in May 2023, and by the MHRA in UK in September 2023, our first product for the treatment of facial angiofibroma associated with the Tuberous Sclerosis Complex (TSC) was launched to the German and UK markets in November 2023.